Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a second brain zap tame tremors on both sides?

NCT ID NCT06974916

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 01, 2026 · Updated 6 times

Summary

This study tests whether a second focused ultrasound treatment on the opposite side of the brain can further reduce tremors in people with essential tremor who already had one treatment. About 100 participants will be randomly assigned to get the second procedure or continue standard care. The main goal is to see if tremor scores improve more in the treated group after 6 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
focused ultrasound (Exablate) procedure
What this could lead to
If successful, this could offer a way to treat tremors on both sides of the body with a non-invasive procedure, potentially reducing the need for medication.
What could go wrong
This is a relatively small, early-stage study (100 people) and focused ultrasound can cause side effects like numbness or balance issues. It is not a cure, and long-term benefits are unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Men and women with an age of 18 years or older (according to local labeling). 2. Willing to participate in the study (i.e., signed ICF). (Willing to be randomized). 3. Patient is able to undergo a high-resolution Computerized Tomography (CT) scan. 4. Patient is able to fit into MRI unit and comply with all contraindications for the specific magnetic resonance (MR) system including and limited to contrast medium should there be needed. 5. The thalamus, sub-thalamus and the pallidum must be apparent on MR imaging. 6. Patient is able to communicate sensations to the physician during the procedure; Procedure does not require general anesthesia. 7. Patient must be able to use the Stop Sonication button freely. 8. Patient willing to have their head shaved prior to the actual treatment. 9. Patient has no history for claustrophobia which is not responding to medications. 10. ET patients who are eligible for second side staged bilateral Exablate thalamotomy treatment (according to local labeling). Time since first intervention is at least 9 months. 11. Available tremor assessment prior to the unilateral Exablate thalamotomy. 12. Patients randomized to the study, irrespective of group allocation should be willing and able to remain in the study for at least 6 months and able to complete the required assessments. Exclusion Criteria: 1. Subject experienced any non-transient neurological event or worsening following the previous Exablate procedure. 2. Patients with MRI related contraindications (e.g. presence of metallic implants incompatibility with MRI, severe claustrophobia, reaction to contrast medium). 3. Patients in whom it is not possible to avoid energy absorbing structures or sensitive tissues (e.g., skull implants, surgical clips, shunts, electrodes, dura patch, skull patch, electrodes, etc.) from the path of the ultrasound beam. 4. Patients with concurrent active infections disease and/or severe allergies with fever. 5. Patients that have been diagnosed with brain tumors or a vascular anomaly. 6. Patients with a history of seizures, brain hemorrhages, stroke within the past year, or any coagulopathy. 7. Patients under anticoagulants and/or anti-platelets drugs known to increase bleeding risk within the duration defined by the half-life of the specific drugs. 8. Patient that has been given any contrast agent (e.g., CT, MRI), within 24 hours before treatment 9. Severe unstable hypertension that cannot be controlled by medications (diastolic Blood Pressure \> 100 on medication). 10. Patients with unstable cardiac status. 11. Patients exhibiting any behavior(s) consistent with ethanol or substance abuse. 12. Cerebrovascular disease (multiple CVA or CVA within 6 months). 13. Patients with risk factors for intraoperative or postoperative bleeding. 14. Imaging shows abnormal finding in CT or/and MRI (e.g., brain tumor, brain vascular malformation, shunt, etc.). 15. Patient has physical subscale score ≥ 16.5 on the Dysphagia Handicap Index or has been diagnosed with dysphagia. 16. Patient with cognitive impairment. 17. Patient with clinically significant abnormal speech function as determined by a speech pathologist.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Essential tremor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    12 sites in 7 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Ascires Hospital_ECG Salud

    ACTIVE_NOT_RECRUITING

    Valencia, 46014, Spain

  • Central Japan International Medical Center

    NOT_YET_RECRUITING

    Minokamo, Gifu, Japan

  • Chang Bing Show Chwan Memorial Hospital

    RECRUITING

    Changhua, 500, Taiwan

  • Clinica Universidad de Navarra

    RECRUITING

    Pamplona, 31008, Spain

  • Fondazione IRCCS Istituto Neurologico Carlo Besta

    RECRUITING

    Milan, 20133, Italy

  • Germans Trias i Pujol Hospital

    RECRUITING

    Badalona, 08916, Spain

  • HM CINAC- Hospital Universitario HM Puerta del Sur

    RECRUITING

    Móstoles, 28938, Spain

  • Kashiwaba Neurology Hospital

    NOT_YET_RECRUITING

    Sapporo, Hokkaido, Japan

  • Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofukai

    NOT_YET_RECRUITING

    Kita-ku, Osaka, Japan

  • National Taiwan University Hospital

    NOT_YET_RECRUITING

    Taipei, 100225, Taiwan

  • The Walton Center

    NOT_YET_RECRUITING

    Liverpool, L97LJ, United Kingdom

  • Turku University Hospital

    RECRUITING

    Turku, FI20520, Finland

  • Universitätsklinikum Schleswig-Holstein, Campus Kiel (UKSH)

    RECRUITING

    Kiel, 24105, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.